Figure 1: Effect of MGMT promoter methylation status in glioblastomas. In GBM,
hypermethylation of the MGMT promoter results in reduction of MGMT protein, which
in turn leads to improved chemosensitivity for TMZ chemotherapy or combined radiochemotherapy.
Therefore, MGMT promoter methylation is correlated with improved
overall survival in these patients. In contrast, GBM patients with unmethylated MGMT
promoter status may have reduced response to radio-/chemotherapy and therefore
worse prognosis (mod from [1, 17]).